Value of monitoring activated clotting time when bivalirudin is used as the sole anticoagulation agent for percutaneous coronary intervention

Edouard Cheneau; Daniel Canos; Pramod K. Kuchulakanti; Seung Woon Rha; Lowell F. Satler; William O. Suddath; Kenneth M. Kent; Augusto D. Pichard; Ron Waksman

doi:10.1016/j.amjcard.2004.05.068

Value of monitoring activated clotting time when bivalirudin is used as the sole anticoagulation agent for percutaneous coronary intervention

Edouard Cheneau, Daniel Canos, Pramod K. Kuchulakanti, Seung Woon Rha, Lowell F. Satler, William O. Suddath, Kenneth M. Kent, Augusto D. Pichard, Ron Waksman

Research output: Contribution to journal › Article › peer-review

24 Citations (Scopus)

Abstract

Anticoagulation during percutaneous coronary intervention (PCI) requires the monitoring of activated clotting time (ACT) to protect from periprocedural ischemic and bleeding complications; however, the optimal ACT values have not been established when PCI is performed with bivalirudin. After 495 consecutive patients treated for coronary artery disease with PCI received bivalirudin as a single anticoagulation agent, it was found that ACT is reproducible when bivalirudin is used during PCI and does not correlate with clinical events.

Original language	English
Pages (from-to)	789-792
Number of pages	4
Journal	American Journal of Cardiology
Volume	94
Issue number	6
DOIs	https://doi.org/10.1016/j.amjcard.2004.05.068
Publication status	Published - 2004 Sept 15
Externally published	Yes

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.amjcard.2004.05.068

Cite this

Cheneau, E., Canos, D., Kuchulakanti, P. K., Rha, S. W., Satler, L. F., Suddath, W. O., Kent, K. M., Pichard, A. D., & Waksman, R. (2004). Value of monitoring activated clotting time when bivalirudin is used as the sole anticoagulation agent for percutaneous coronary intervention. American Journal of Cardiology, 94(6), 789-792. https://doi.org/10.1016/j.amjcard.2004.05.068

@article{3994ea18d7c14820a21e02151d01b542,

title = "Value of monitoring activated clotting time when bivalirudin is used as the sole anticoagulation agent for percutaneous coronary intervention",

abstract = "Anticoagulation during percutaneous coronary intervention (PCI) requires the monitoring of activated clotting time (ACT) to protect from periprocedural ischemic and bleeding complications; however, the optimal ACT values have not been established when PCI is performed with bivalirudin. After 495 consecutive patients treated for coronary artery disease with PCI received bivalirudin as a single anticoagulation agent, it was found that ACT is reproducible when bivalirudin is used during PCI and does not correlate with clinical events.",

author = "Edouard Cheneau and Daniel Canos and Kuchulakanti, {Pramod K.} and Rha, {Seung Woon} and Satler, {Lowell F.} and Suddath, {William O.} and Kent, {Kenneth M.} and Pichard, {Augusto D.} and Ron Waksman",

year = "2004",

month = sep,

day = "15",

doi = "10.1016/j.amjcard.2004.05.068",

language = "English",

volume = "94",

pages = "789--792",

journal = "American Journal of Cardiology",

issn = "0002-9149",

publisher = "Elsevier Inc.",

number = "6",

}

TY - JOUR

T1 - Value of monitoring activated clotting time when bivalirudin is used as the sole anticoagulation agent for percutaneous coronary intervention

AU - Cheneau, Edouard

AU - Canos, Daniel

AU - Kuchulakanti, Pramod K.

AU - Rha, Seung Woon

AU - Satler, Lowell F.

AU - Suddath, William O.

AU - Kent, Kenneth M.

AU - Pichard, Augusto D.

AU - Waksman, Ron

PY - 2004/9/15

Y1 - 2004/9/15

N2 - Anticoagulation during percutaneous coronary intervention (PCI) requires the monitoring of activated clotting time (ACT) to protect from periprocedural ischemic and bleeding complications; however, the optimal ACT values have not been established when PCI is performed with bivalirudin. After 495 consecutive patients treated for coronary artery disease with PCI received bivalirudin as a single anticoagulation agent, it was found that ACT is reproducible when bivalirudin is used during PCI and does not correlate with clinical events.

AB - Anticoagulation during percutaneous coronary intervention (PCI) requires the monitoring of activated clotting time (ACT) to protect from periprocedural ischemic and bleeding complications; however, the optimal ACT values have not been established when PCI is performed with bivalirudin. After 495 consecutive patients treated for coronary artery disease with PCI received bivalirudin as a single anticoagulation agent, it was found that ACT is reproducible when bivalirudin is used during PCI and does not correlate with clinical events.

UR - http://www.scopus.com/inward/record.url?scp=4544241581&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4544241581&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2004.05.068

DO - 10.1016/j.amjcard.2004.05.068

M3 - Article

C2 - 15374791

AN - SCOPUS:4544241581

SN - 0002-9149

VL - 94

SP - 789

EP - 792

JO - American Journal of Cardiology

JF - American Journal of Cardiology

IS - 6

ER -

Value of monitoring activated clotting time when bivalirudin is used as the sole anticoagulation agent for percutaneous coronary intervention

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this